Securities and Exchange Commission filings indicate that Oxford Finance LLC acquired 1.62 million common shares, representing 16.5% ownership in the clinical-stage company. Oxford Finance, the ...

Kala Bio secures $6 million investment as CEO changes amid trial failure ...

KALA BIO Inc. (NASDAQ: KALA) jumped 37.87% to $0.88 in after-hours trading on Tuesday. Check out the current price of KALA stock here. According to Benzinga Pro data, the stock closed the regular ...

SHAKOPEE, Minn. — A woman is dead after a crash in Shakopee late Sunday night. The Minnesota State Patrol reported that 46-year-old Kala Karlene Henry of Chaska was headed south on Highway 169 near ...

ARLINGTON, Mass. (AP) — ARLINGTON, Mass. (AP) — KALA BIO, Inc. (KALA) on Wednesday reported a loss of $7.6 million in its third quarter. On a per-share basis, the Arlington, Massachusetts-based ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Arlington biotech Kala Bio has ...

CBSE Class 12 Exam Pattern and Marking Scheme 2026: The Central Board of Secondary Education (CBSE) will conduct the Class 12 Hindi exam in 2026 based on a specific pattern. Understanding this pattern ...

Kala Bio said it laid off most of its employees after receiving notice that its lender, Oxford Finance, intends to foreclose on all of its remaining assets. The move follows the biotech company's ...

Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of ...

Kala Bio receives default notice, $29.1 million loan declared immediately due ...

Shares of Kala Bio plummeted Monday after the company said a study of its treatment for Persistent Corneal Epithelial Defect, an eye defect, missed its primary endpoints and it would stop development ...

Sept 29 (Reuters) - Kala Bio (KALA.O), opens new tab will stop developing its experimental treatment for a type of eye condition after it failed to meet the main goal in a mid-stage study, sending the ...